Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Summary

The trial investigates the efficacy of adoptive immunotherapy with haploidentical natural killer cells compared to standard chemotherapy (after first complete remission) in patients with a high-risk acute myeloid leukemia being older than 65 years of age and not eligible for allogeneic transplantation

Timeline

Start

2015-09

Primary completion

2017-04-22

Completion

2017-04-22

Outcome

Outcome not reported

Stopped (Enrollment): “low recruitment rate”

Drugs

Indications